EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice

Tair Ben-Porat, Shiri Sherf-Dagan, Marilou Côté, Cherie Josephine Miner, Assaf Buch

Advances in Nutrition · 2025

DOI: 10.1016/j.advnut.2025.100522 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Nutrition, 2025. Verfasst von Tair Ben-Porat und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel. Electronic address: tbenporat@univ.haifa.…. Hauptthemen laut MEDLINE: Incretins, Obesity, Nutritional Status, Anti-Obesity Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several novel incretin-based obesity management medications (OMMs) have recently been approved for chronic weight management in adults with obesity or overweight. These agents have demonstrated substantial weight reduction effects alongside glucoregulatory and cardioprotective benefits. However, the use of incretin-based OMMs presents nutritional challenges that remain insufficiently addressed. These include side effects such as gastrointestinal disturbances and loss of lean body mass, which may compromise nutritional status, reduce energy expenditure, and heighten risk of rebound weight gain, sarcopenia, and frailty. Moreover, although these medications effectively suppress energy intake and reduce food quantity, they may also have unintended effects on diet quality, potentially influencing macronutrient distribution, ultraprocessed food consumption, risk of vitamin and mineral deficiencies, and disordered eating behaviors, which could undermine long-term weight maintenance and the cardiometabolic benefits achieved through these pharmacotherapy agents. Emerging evidence suggests that specific dietary and behavioral strategies, such as higher protein intake, resistance training, nutrient-dense eating patterns, and fostering adaptive eating behaviors, may help mitigate nutritional challenges and physiologic deterioration during significant weight reduction while also supporting cardiometabolic health maintenance. However, the application of these strategies as adjunct treatments alongside the new OMMs remains unclear. This narrative review summarizes the current literature on these issues and proposes dietary interventions and behavioral modification strategies aimed at mitigating the adverse effects that can be associated with incretin-based OMMs. These considerations are increasingly important given the expanding use of these medications, the degree of weight reduction they induce, and the implications for specific at-risk groups, including aging populations prone to muscle and functional decline and individuals with pre-existing conditions of nutritional deficiencies, chronic diseases, and disordered eating patterns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsObesityNutritional StatusAnti-Obesity AgentsObesity ManagementHumansWeight LossDietFeeding Behavior

Stichwörter der Autor:innen

GLP-1 and GIP receptor agonistsadverse effectsbehavioral interventionseating behaviorslean mass losslifestyle modificationsnutritionobesityobesity management medicationsweight reduction

Substanzen

IncretinsAnti-Obesity Agents

Autor:innen und Institutionen

  • School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel. Electronic address: tbenporat@univ.haifa.ac.il.
  • Department of Nutrition Sciences, School of Health Sciences, Ariel University, Ariel, Israel; Department of Nutrition, Tel-Aviv Assuta Medical Center, Tel-Aviv, Israel.
  • Département des Fondements et Pratiques en Éducation, Faculté des Sciences de l'Éducation, Université Laval, Quebec City, Québec, Canada; Centre Nutrition, Santé et Société (NUTRISS), INAF, Université Laval, Quebec City…
  • School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel.
  • Department of Nutrition Sciences, School of Health Sciences, Ariel University, Ariel, Israel; Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Förderung

  • Novo Nordisk

Zitieren

APA

Ben-Porat, T., Sherf-Dagan, S., Côté, M., Miner, C. J., & Buch, A. (2025). Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice. Advances in Nutrition. https://doi.org/10.1016/j.advnut.2025.100522

Vancouver

Ben-Porat T, Sherf-Dagan S, Côté M, Miner CJ, Buch A. Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice. Advances in Nutrition. 2025. doi:10.1016/j.advnut.2025.100522

BibTeX
@article{BenPorat2025,
  author = {Ben-Porat, Tair and Sherf-Dagan, Shiri and Côté, Marilou and Miner, Cherie Josephine and Buch, Assaf},
  title = {Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice},
  journal = {Advances in Nutrition},
  year = {2025},
  doi = {10.1016/j.advnut.2025.100522}
}
Kostenlos starten →